Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.50
- Piotroski Score 3.00
- Grade Buy
- Symbol (TRVI)
- Company Trevi Therapeutics, Inc.
- Price $3.00
- Changes Percentage (-1.32%)
- Change -$0.04
- Day Low $2.86
- Day High $3.05
- Year High $4.00
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $12.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.34
- Trailing P/E Ratio -7.18
- Forward P/E Ratio -7.18
- P/E Growth -7.18
- Net Income $-29,065,000
Income Statement
Quarterly
Annual
Latest News of TRVI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.
Ownership research and analyst forecasts data provide insights into stock opportunities. Institutions hold 37% stake in Trevi Therapeutics, impacting market cap fluctuations. Hedge funds and private e...
By Yahoo! Finance | 2 months ago -
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
Investors are attracted to unprofitable companies like Salesforce.com, but they must be cautious of those that burn through cash and collapse. Trevi Therapeutics has a cash runway of 2....
By Yahoo! Finance | 4 months ago
